Hypoxic Ischemic Encephalopathy

Normal BrainNormal Brain
HIE + HypothermiaHIE + Hypothermia
HIE + RLS-0071HIE + RLS-0071

RLS-0071 also significantly improves neurocognitive function of HIE-model rats. Below are test results from a Barnes maze assessment, which measures a rat’s ability to remember escape hole locations. HIE-induced rats treated with RLS-0071 have a significantly improved ability to recall the location of the escape hole.

Hypoxia + Ligation Hypoxia +
Hypoxia + Ligation + Hypothermia Hypoxia +
Ligation +
Hypoxia + Ligation + RLS-0071 Hypoxia +
Ligation +

Realta Was Formed With Strong Support From Key HIE Patient Advocacy Groups

ReAlta has partnered with Hope for HIE, a leading organization providing resources for awareness, education, advocacy, and support surrounding neonatal and pediatric HIE. Serving a worldwide community, the organization provides a comprehensive support network for families, collaborates with research and medical professionals, and leads advocacy initiatives to reduce incidence and increase quality of life for those affected by HIE. Hope for HIE is a 501(c)3 non-profit. For more information, please visit www.hopeforhie.org.

ReAlta, as a platinum level partner, is sponsoring the development of educational resources that will help Hope for HIE’s community better understand the impacts of HIE in childhood development.

Our Goals:

— Significantly increase the survival rate of babies born with birth asphyxia world-wide

— Enhance the neurocognitive outcomes of HIE survivors

— Make the RLS-0071 drug product available to professionals and families around the world

Acute Lung Injury

Acute lung injury (ALI) is the pulmonary manifestation of an acute systemic inflammatory process characterized clinically by pulmonary infiltrates, hypoxemia and edema.

Learn More
Hypoxic Ischemic Encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.

Learn More
Platelet Refractoriness

Platelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.

Learn More